Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of CorMedix Inc (NASDAQ: CRMD) closed at $10.78 in the last session, down -3.41% from day before closing price of $11.16. In other words, the price has decreased by -$3.41 from its previous closing price. On the day, 2.11 million shares were traded. CRMD stock price reached its highest trading level at $11.274 during the session, while it also had its lowest trading level at $10.675.
Ratios:
We take a closer look at CRMD’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.43 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 27.77. For the most recent quarter (mrq), Quick Ratio is recorded 7.52 and its Current Ratio is at 7.82. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On June 30, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $20.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 06 ’25 when Erin Mistry bought 13,908 shares for $10.97 per share.
Kaplan Myron bought 25,000 shares of CRMD for $275,500 on Oct 23 ’25. The Director now owns 201,034 shares after completing the transaction at $11.02 per share. On Sep 12 ’25, another insider, DUNTON ALAN W, who serves as the Director of the company, sold 10,000 shares for $13.13 each. As a result, the insider received 131,300 and left with 40,250 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 844602816 and an Enterprise Value of 614439680. As of this moment, CorMedix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.44, and their Forward P/E ratio for the next fiscal year is 4.34. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.95 while its Price-to-Book (P/B) ratio in mrq is 3.65. Its current Enterprise Value per Revenue stands at 5.058 whereas that against EBITDA is 12.325.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.31, which has changed by -0.037931025 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $17.43, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is -7.89%, while the 200-Day Moving Average is calculated to be -3.68%.
Shares Statistics:
According to the various share statistics, CRMD traded on average about 3.49M shares per day over the past 3-months and 2319650 shares per day over the past 10 days. A total of 74.62M shares are outstanding, with a floating share count of 70.17M. Insiders hold about 10.44% of the company’s shares, while institutions hold 45.29% stake in the company. Shares short for CRMD as of 1760486400 were 16179795 with a Short Ratio of 4.64, compared to 1757894400 on 16671740. Therefore, it implies a Short% of Shares Outstanding of 16179795 and a Short% of Float of 20.849999999999998.
Earnings Estimates
Current recommendations for the stock of the company come from 7.0 analysts. The consensus estimate for the next quarter is $0.82, with high estimates of $1.24 and low estimates of $0.59.
Analysts are recommending an EPS of between $2.82 and $1.52 for the fiscal current year, implying an average EPS of $2.08. EPS for the following year is $2.49, with 7.0 analysts recommending between $2.91 and $2.19.
Revenue Estimates
According to 7 analysts,. The current quarter’s revenue is expected to be $86.02M. It ranges from a high estimate of $125M to a low estimate of $65M. As of. The current estimate, CorMedix Inc’s year-ago sales were $11.46MFor the next quarter, 7 analysts are estimating revenue of $118.85M. There is a high estimate of $140M for the next quarter, whereas the lowest estimate is $97.5M.
A total of 7 analysts have provided revenue estimates for CRMD’s current fiscal year. The highest revenue estimate was $343.82M, while the lowest revenue estimate was $249M, resulting in an average revenue estimate of $283.66M. In the same quarter a year ago, actual revenue was $43.47MBased on 7 analysts’ estimates, the company’s revenue will be $410.87M in the next fiscal year. The high estimate is $487.03M and the low estimate is $304.1M.
